Sign up
Log in
News
MDWD
19.37
-0.82%
-0.16
Weekly Report: what happened at MDWD last week (0715-0719)?
Weekly Report · 4d ago
Mediwound’s Bright Outlook: Strategic Investment and Acquisition Potential Underpin Buy Rating
TipRanks · 07/17 15:47
MediWound rises on €16.25 million funding from European Innovation Council
MediWound to receive €16.25 million funding from European Innovation Council. The funding will significantly advance the development of a new treatment for diabetic foot ulcers. Shares of the company are up about 1.2% in early trade. The company will receive the funding from the EIC for four years.
Seeking Alpha · 07/16 13:46
MediWound Price Target Maintained With a $28.00/Share by HC Wainwright & Co.
Dow Jones · 07/16 12:39
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target
Benzinga · 07/16 12:29
MediWound Accelerates DFU Treatment with EIC Funds
TipRanks · 07/16 11:58
BRIEF-Mediwound Announces €16.25 Million Funding From The European Innovation Council Accelerator Program
Reuters · 07/16 11:42
Analysts’ Top Healthcare Picks: Checkpoint Therapeutics (CKPT), Mediwound (MDWD)
TipRanks · 07/16 10:30
MediWound and Teva Amend Settlement Terms
TipRanks · 07/15 20:29
MediWound Files Amendment To Settlement Agreement With Teva; Under Amendment, Co Will Prepay Teva $4M As Final Payment Due From Company Under Agreement; 50% Of Prepayment In Cash, 50% In Form Of Ordinary Shares Of Co To Be Issued By Co To Teva
Benzinga · 07/15 20:13
MediWould announces $25M private placement financing
Healthcare MediWould announces $25M private placement financing. MediWound Ltd. Plans to use the net proceeds to advance EscharEx pre-commercial activities. The company is expected to close the offering within several days. Medi would is a subsidiary of Israel-based pharmaceutical company.
Seeking Alpha · 07/15 14:20
Buy Rating Affirmed for Mediwound: Strategic Alliances and Financial Infusions Signal Strong Market Position for EscharEx
TipRanks · 07/15 13:05
Weekly Report: what happened at MDWD last week (0708-0712)?
Weekly Report · 07/15 11:51
Mölnlycke Invests $15M in MediWound to Enhance Wound Care Solutions
Mölnlycke Health Care announces investment of US $15m in MediWound Ltd. The company is a leader in non-surgical wound debridement. Debridement is a standard of care step to prepare the wound bed for healing.
Benzinga · 07/15 11:38
MÖLNLYCKE® HEALTH CARE ANNOUNCES US $15M INVESTMENT IN NEXT-GENERATION ENZYMATIC THERAPEUTICS COMPANY MEDIWOUND LTD
Reuters · 07/15 11:32
MediWound Ltd. Announces New Share Purchase Deal
TipRanks · 07/15 11:29
MediWound Announces $25M Strategic Private Placement Financing Of 1.45M Shares At $17.20/Share To Advance EscharEx Pre-Commercial Activities
MediWound Ltd. Has entered into a definitive share purchase agreement with several new and existing investors. The agreement includes the sale and purchase of 1,453,488 shares of the Company's ordinary shares. The gross proceeds from the PIPE Offering are $25 million. The company is the world leader in enzymatic therapeutics for tissue repair.
Benzinga · 07/15 11:09
MEDIWOUND LTD - TO USE PROCEEDS TO ADVANCE ESCHAREX PRE-COMMERCIAL ACTIVITIES
Reuters · 07/15 11:00
MEDIWOUND LTD - PURCHASE PRICE SET AT $17.20 PER SHARE
Reuters · 07/15 11:00
MediWound Announces $25 Million Strategic Private Placement Financing
MediWound Ltd. Is the world leader in next-generation enzymatic therapeutics for tissue repair. The company has entered into a definitive share purchase agreement with several new and existing investors. Mölnlycke Health Care is a world-leading MedTech company specializing in wound care.
Barchart · 07/15 06:00
More
Webull provides a variety of real-time MDWD stock news. You can receive the latest news about Mediwound through multiple platforms. This information may help you make smarter investment decisions.
About MDWD
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.